← Eichor
Study identifier: NCT06280755 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

Condition: Multiple Sclerosis · NMO Spectrum Disorder · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease  ·  Sponsor: icometrix

PhaseN/A
Planned participants7000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.

This description comes directly from the study's public registry record.

Talk to the study team

Diana M Sima, PhD  ·  +32 16 369 000  ·  diana.sima@icometrix.com

Vincenzo Anania  ·  +32 16 369 000  ·  vincenzo.anania@icometrix.com

Always discuss trial participation with your own doctor first.

Locations (3)

General University Hospital PraguePrague, Praha 2, CzechiaRecruiting
Katholisches Klinikum Bochum - St. Joseph-HospitalBochum, Bochum, GermanyRecruiting
ERC Charité - Universitätsmedizin BerlinBerlin, State of Berlin, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06280755